On December 31, 2008, Bioject Medical Technologies Inc. (the "Company") entered into an Amendment to Employment Agreement with Dr. Richard Stout, its Executive Vice President and Chief Medical Officer. The primary effect of the amendment is to delay the payment of Dr. Stout's severance if necessary to comply with
Section 409A of the Internal Revenue Code and to provide that severance payments will be made on regularly scheduled payroll dates. The amendment is filed as Exhibit 10.1 hereto.

Also on December 31, 2008, the Company entered into a Second Amendment to Standard Employment Agreement with Ms. Christine Farrell, its Vice President of Finance. The primary effect of the amendment is to provide for severance benefits and accelerated vesting if her employment is terminated for Good Reason (as defined in the amendment). Her prior agreement provided for severance and accelerated vesting only if she was terminated without cause. The amendment is filed as Exhibit 10.2 hereto.

(d) Exhibits

The following exhibits are filed herewith and this list is intended to constitute the exhibit index:

10.1    Amendment to Employment Agreement, dated December 31, 2008, between
        Bioject Medical Technologies Inc. and Dr. Richard Stout.

10.2    Second Amendment to Standard Employment Agreement, dated December 31,
        2008, between Bioject Medical Technologies Inc. and Ms. Christine Farrell.